P170. Prevalence of hepatitis B viral markers in Korean patients with inflammatory bowel disease: ineffective antibody formation in young patients
E.Y. Kim1, K.B. Cho2, E.S. Kim2, K.S. Park2, S.W. Jeon3, W.J. Kim4, K.O. Kim5, B.I. Jang5, C.H. Yang6, 1Catholic University of Daegu School of Medicine, Internal Medicine, Daegu, South Korea, 2Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 3Kyungpook National University School of Medicine, Internal Medicine, Daegu, South Korea, 4Soon Chun Hyang University, Internal Medicine, Kumi, South Korea, 5Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, 6Dongguk University Hospital, Internal Medicine, Kyungju, South Korea
There has been no data regarding the prevalence of hepatitis B (HBV) viral markers in inflammatory bowel disease (IBD) patients in Korea which is an endemic area of HBV. The aims of the study are to assess the prevalence of HBV markers in IBD patients and to compare with that of controls.
This cross-sectional multicenter study enrolled 513 IBD patients (241 Crohn's disease [CD] and 272 ulcerative colitis [UC]) consecutively whose HBsAg and anti-HBs were able to evaluate. Among them, anti-HBc was available in 357 patients. These markers were compared with those of 1020 sex and age matched control subjects.
The prevalence of HBsAg of IBD patients was 3.7% and there was no significant difference between groups (CD 4.1%, UC 3.3%, control 4.4%, p = 0.537). The prevalence of anti-HBs and anti-HBc were significantly lower in CD than UC or control group (anti-HBs: CD 55.6%, UC 67.3%, control 73.3%, p < 0.001; anti-HBc: CD 23.8%, UC 35.2%, control 35.9%, p = 0.01). Subgroups analysis according to age showed significantly lower prevalence of anti-HBs in IBD patients than control in subgroups of age 29 and below, and 30–49 whereas there was no difference in subgroups of age 50 and above. Regarding HBsAg and anti-HBc, no difference between groups was observed in each age subgroup. Effective vaccination (anti-HBs, without anti-HBc) was present in 38.1% patients which was lower than that of control (44.4%) (p = 0.04). Multivariate analysis revealed that male, age at sampling, and blood transfusion were independent risk factors of non-effective vaccination.
The prevalence of HBsAg in Korean IBD patients is comparable to that of control subjects. However, antibody formation seems to be ineffective in IBD patients, especially young age group. The low percentage of anti-HBs warrants intensive vaccination strategy in young IBD patients in this HBV endemic area.